-

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:

  • Stifel 2026 Healthcare Conference. The Company will attend on Thursday, November 12, and will provide a corporate presentation at 9:20 a.m. – 9:50 a.m. ET.
  • Jefferies 2026 Global Healthcare Conference in London. The Company will attend and participate in one-on-one meetings from Monday, November 16 – Wednesday, November 18.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394 or PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors. For more information, please visit www.fore.bio or follow us on X and LinkedIn.

Contacts

Investors and Media:
Argot Partners
212.600.1902 | ForeBio@argotpartners.com

Industry:

FORE Biotherapeutics

Release Versions
English

Contacts

Investors and Media:
Argot Partners
212.600.1902 | ForeBio@argotpartners.com

More News From FORE Biotherapeutics

FORE Biotherapeutics to Present New Clinical and Preclinical Plixorafenib Data at Upcoming Oncology Medical Meetings

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two abstracts that have been selected for presentation at two prestigious oncology medical meetings. The first is an oral presentation highlighting long-term efficacy and safety data from a Phase 1/2a study evaluating plixorafenib in patients with BRAF V600 primary CNS tumors and will be presented at the upcom...

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will participate at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference. The Company will attend and participate in one-on-one meetings on Tuesday, September 8. Morgan Stanley 24th Annual Global Healthcare Conference. The Company will attend on Tuesday, September 15, and will provide a corporate presentation at 7:45 a.m. ET. Management will host and participate in one-on-one meetin...

FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that following the first of two pre-specified interim efficacy analyses for the FORTE basket study evaluating plixorafenib as a monotherapy in patients with advanced solid tumors with BRAF fusions, including recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, the Independent Data Monit...
Back to Newsroom